Advisory Committee Recommends US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes

ADELPHI, Md. -- An FDA advisory panel has voted overwhelmingly to recommend approval of AstraZeneca's investigational antiplatelet drug ticagrelor (Brilinta), saying it appears more effective than clopidogrel (Plavix) for patients with acute coronary syndrome who will be treated either medically or with PCI.